165 related articles for article (PubMed ID: 29440684)
21. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
22. Internalization and desensitization of the human glucose-dependent-insulinotropic receptor is affected by N-terminal acetylation of the agonist.
Ismail S; Dubois-Vedrenne I; Laval M; Tikhonova IG; D'Angelo R; Sanchez C; Clerc P; Gherardi MJ; Gigoux V; Magnan R; Fourmy D
Mol Cell Endocrinol; 2015 Oct; 414():202-15. PubMed ID: 26225752
[TBL] [Abstract][Full Text] [Related]
23. GIP(3-30)NH
Sparre-Ulrich AH; Gabe MN; Gasbjerg LS; Christiansen CB; Svendsen B; Hartmann B; Holst JJ; Rosenkilde MM
Biochem Pharmacol; 2017 May; 131():78-88. PubMed ID: 28237651
[TBL] [Abstract][Full Text] [Related]
24. 110mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine tumors with PET.
Lubberink M; Tolmachev V; Widström C; Bruskin A; Lundqvist H; Westlin JE
J Nucl Med; 2002 Oct; 43(10):1391-7. PubMed ID: 12368379
[TBL] [Abstract][Full Text] [Related]
25. 99mTc-labeled estradiol as an estrogen receptor probe: Preparation and preclinical evaluation.
Xia X; Feng H; Li C; Qin C; Song Y; Zhang Y; Lan X
Nucl Med Biol; 2016 Jan; 43(1):89-96. PubMed ID: 26466867
[TBL] [Abstract][Full Text] [Related]
26. Imaging of the Glucose-Dependent Insulinotropic Polypeptide Receptor Using a Novel Radiolabeled Peptide Rationally Designed Based on Endogenous GIP and Synthetic Exendin-4 Sequences.
Velikyan I; Bossart M; Haack T; Laitinen I; Estrada S; Johansson L; Pierrou S; Wagner M; Eriksson O
Pharmaceuticals (Basel); 2022 Dec; 16(1):. PubMed ID: 36678558
[TBL] [Abstract][Full Text] [Related]
27. Glucose-dependent insulinotropic polypeptide (GIP) and its receptor (GIPR): cellular localization, lesion-affected expression, and impaired regenerative axonal growth.
Buhren BA; Gasis M; Thorens B; Müller HW; Bosse F
J Neurosci Res; 2009 Jun; 87(8):1858-70. PubMed ID: 19170165
[TBL] [Abstract][Full Text] [Related]
28. A novel GIP receptor splice variant influences GIP sensitivity of pancreatic beta-cells in obese mice.
Harada N; Yamada Y; Tsukiyama K; Yamada C; Nakamura Y; Mukai E; Hamasaki A; Liu X; Toyoda K; Seino Y; Inagaki N
Am J Physiol Endocrinol Metab; 2008 Jan; 294(1):E61-8. PubMed ID: 17971513
[TBL] [Abstract][Full Text] [Related]
29. Preclinical studies of SPECT and PET tracers for NET.
Brom M; Boerman O; Gotthardt M; Oyen WJ
PET Clin; 2014 Jan; 9(1):63-9. PubMed ID: 25029935
[TBL] [Abstract][Full Text] [Related]
30. Clinical application of SPECT-CT with 99mTc-Tektrotyd in bronchial and thymic neuroendocrine tumors (NETs).
Sergieva S; Robev B; Dimcheva M; Fakirova A; Hristoskova R
Nucl Med Rev Cent East Eur; 2016; 19(2):81-7. PubMed ID: 27479885
[TBL] [Abstract][Full Text] [Related]
31. Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents.
Gasbjerg LS; Gabe MBN; Hartmann B; Christensen MB; Knop FK; Holst JJ; Rosenkilde MM
Peptides; 2018 Feb; 100():173-181. PubMed ID: 29412817
[TBL] [Abstract][Full Text] [Related]
32. Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours.
Sainz-Esteban A; Olmos R; González-Sagrado M; González ML; Ruiz MÁ; García-Talavera P; Gamazo C; Villanueva JG; Cobo A; de Luis D
Nucl Med Commun; 2015 Mar; 36(3):251-9. PubMed ID: 25369750
[TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer.
Dalm SU; Martens JW; Sieuwerts AM; van Deurzen CH; Koelewijn SJ; de Blois E; Maina T; Nock BA; Brunel L; Fehrentz JA; Martinez J; de Jong M; Melis M
J Nucl Med; 2015 May; 56(5):752-7. PubMed ID: 25791989
[TBL] [Abstract][Full Text] [Related]
34. 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients.
Pfeifer A; Knigge U; Binderup T; Mortensen J; Oturai P; Loft A; Berthelsen AK; Langer SW; Rasmussen P; Elema D; von Benzon E; Højgaard L; Kjaer A
J Nucl Med; 2015 Jun; 56(6):847-54. PubMed ID: 25952736
[TBL] [Abstract][Full Text] [Related]
35. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
Janson ET; Westlin JE; Ohrvall U; Oberg K; Lukinius A
J Nucl Med; 2000 Sep; 41(9):1514-8. PubMed ID: 10994731
[TBL] [Abstract][Full Text] [Related]
36. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting.
Nock BA; Maina T; Krenning EP; de Jong M
J Nucl Med; 2014 Jan; 55(1):121-7. PubMed ID: 24287321
[TBL] [Abstract][Full Text] [Related]
37. Physiological Uptake in the Pancreatic Head on Somatostatin Receptor Scintigraphy Using [111In-DTPA]Octreotide: Incidence and Mechanism.
Brabander T; Teunissen J; Kwekkeboom D
Clin Nucl Med; 2017 Jan; 42(1):15-19. PubMed ID: 27775943
[TBL] [Abstract][Full Text] [Related]
38.
Fujiwara K; Tsuji AB; Sudo H; Sugyo A; Akiba H; Iwanari H; Kusano-Arai O; Tsumoto K; Momose T; Hamakubo T; Higashi T
Ann Nucl Med; 2020 Jan; 34(1):13-23. PubMed ID: 31605356
[TBL] [Abstract][Full Text] [Related]
39. Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: demonstration by a receptor antagonist.
Lewis JT; Dayanandan B; Habener JF; Kieffer TJ
Endocrinology; 2000 Oct; 141(10):3710-6. PubMed ID: 11014226
[TBL] [Abstract][Full Text] [Related]
40. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
